Nicholas Campbell - Mediantechn Chief Commercial Officer
| ALMDT Stock | EUR 3.34 0.13 3.75% |
Executive
Mr. Nicholas Campbell serves as Chief Commercial Officer of the Company. As Chief Commercial Officer, Nicholas Campbell is responsible for all commercial activity and strategy execution across the MEDIAN organization. He has more than 18 years of biopharmaceutical industry experience and a proven track record of sales leadership, market building, strategic partnering and driving business growth across multiple geographic regions, service lines and organizational structures . Previously, Nicholas served as Vice President and Managing Director within Quintiles Customer Solutions Management Group with prior leadership positions as global head of sales for its early clinical, cardiac safety and genomic service businesses and Head of Sales for Quintiles East Asia. Nicholas Campbell holds a BS with Honors from University of Wolverhampton, UK and a MBA from the University of Plymouth Business School, UK. since 2016.
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 33 4 93 33 37 77 |
| Web | https://www.mediantechnologies.com |
Mediantechn Management Efficiency
The company has return on total asset (ROA) of (0.2475) % which means that it has lost $0.2475 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (5.1128) %, meaning that it generated substantial loss on money invested by shareholders. Mediantechn's management efficiency ratios could be used to measure how well Mediantechn manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 14 records | EXECUTIVE Age | ||
| Pierre Dodion | Innate Pharma | 61 | |
| MarieBleuenn Terrier | Cellectis | 41 | |
| Stephan Reynier | Cellectis | N/A | |
| Philippe Pouletty | Innate Pharma | 55 | |
| Mailys Ferrere | Innate Pharma | 55 | |
| Veronique Chabernaud | Innate Pharma | 56 | |
| JeanYves Blay | Innate Pharma | 55 | |
| Philippe Duchateau | Cellectis | 60 | |
| Marcus Schindler | Innate Pharma | 51 | |
| Michael Caligiuri | Innate Pharma | 57 | |
| JeanCharles Soria | Innate Pharma | N/A | |
| Karsten Knudsen | Innate Pharma | 44 | |
| Patrick Langlois | Innate Pharma | 70 | |
| Eric Vivier | Innate Pharma | N/A | |
Management Performance
| Return On Equity | -5.11 | |||
| Return On Asset | -0.25 |
Mediantechn Leadership Team
Elected by the shareholders, the Mediantechn's board of directors comprises two types of representatives: Mediantechn inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mediantechn. The board's role is to monitor Mediantechn's management team and ensure that shareholders' interests are well served. Mediantechn's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mediantechn's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gerard Milhiet, Co-Founder, Executive VP and Director | ||
| Takashi Hayashi, Managing Japan | ||
| Bill Broderick, VP Services | ||
| Jacques Souquet, Director | ||
| Ciaran Cooper, Clinical Devel | ||
| MD MS, Chief Officer | ||
| Kapil Dhingra, Director | ||
| Nicholas Campbell, Chief Commercial Officer | ||
| Jerome Windsor, Vice President - Business Development Pharma | ||
| Otello Stampacchia, Director | ||
| Takashi Mori, Director - Representative of Canon Inc | ||
| Dennis Atkinson, Director - Representative of ePlanet Ventures Ltd | ||
| Fredrik Brag, Co-Founder, Chairman, CEO and Pres | ||
| Timothy Haines, Director | ||
| JeanChristophe Montigny, Chief Officer | ||
| Nohza Boujemaa, Chief Science and Innovation Officer | ||
| Michael Auffret, Head of Regulatory Affair and VP of Product Management and Regulatory | ||
| Marjorie Kooman, VP Relations | ||
| Emmanuelle Leygues, Head Communications | ||
| Franck Lescure, Director - Representative of Auriga Partners | ||
| Arnaud Butzbach, Co-Founder, CTO and VP of Operations | ||
| Oran Muduroglu, Director | ||
| Jeanne Hecht, COO | ||
| Nicolas Dano, Chief Unit | ||
| Souhil Zaim, Member of the Executive Committee, Medical Director | ||
| Sophie Campagno, Chief Services | ||
| Bernard Reymann, CFO |
Mediantechn Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mediantechn a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.11 | |||
| Return On Asset | -0.25 | |||
| Profit Margin | (0.80) % | |||
| Operating Margin | (0.77) % | |||
| Current Valuation | 117.65 M | |||
| Shares Outstanding | 15.74 M | |||
| Shares Owned By Insiders | 28.90 % | |||
| Shares Owned By Institutions | 18.72 % | |||
| Price To Earning | (13.07) X | |||
| Price To Book | 271.96 X |
Pair Trading with Mediantechn
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mediantechn position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mediantechn will appreciate offsetting losses from the drop in the long position's value.Moving together with Mediantechn Stock
| 0.64 | ALTHE | Theradiag SA Earnings Call Tomorrow | PairCorr |
| 0.64 | GNFT | Genfit | PairCorr |
| 0.61 | ALEUP | Europlasma SA Earnings Call Today | PairCorr |
The ability to find closely correlated positions to Mediantechn could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mediantechn when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mediantechn - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mediantechn to buy it.
The correlation of Mediantechn is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mediantechn moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mediantechn moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mediantechn can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Mediantechn. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Mediantechn Stock analysis
When running Mediantechn's price analysis, check to measure Mediantechn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mediantechn is operating at the current time. Most of Mediantechn's value examination focuses on studying past and present price action to predict the probability of Mediantechn's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mediantechn's price. Additionally, you may evaluate how the addition of Mediantechn to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |